Skip to content
lifestyle.humane.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ITM Isotope Technologies Munich SE
Correction: ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026
October 20, 2026
ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026
October 20, 2026
ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026
October 7, 2026
ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
September 27, 2026
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
September 23, 2026
ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)
August 10, 2026
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
July 27, 2026
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
July 7, 2026
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
June 29, 2026
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
June 29, 2026
1
2
Next Page
→